| Item Type | Name |
|
Concept
|
S Phase
|
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
G2 Phase
|
|
Academic Article
|
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma.
|
|
Academic Article
|
Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma.
|
|
Academic Article
|
Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
|
|
Academic Article
|
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma.
|
|
Academic Article
|
Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
|
|
Academic Article
|
Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
|
|
Academic Article
|
Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.
|
|
Academic Article
|
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
|
|
Academic Article
|
Alteration of integrated optical density and intercellular structure after induction chemotherapy and survival in lung carcinoma patients treated surgically.
|
|
Academic Article
|
Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study.
|
|
Academic Article
|
EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma.
|
|
Academic Article
|
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
|
|
Academic Article
|
An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells.
|
|
Academic Article
|
Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer.
|
|
Academic Article
|
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
|
|
Academic Article
|
A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586).
|
|
Academic Article
|
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
|
|
Academic Article
|
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
|
|
Academic Article
|
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
|
|
Academic Article
|
Chemoradiation in locally advanced non-small cell lung cancer.
|
|
Academic Article
|
ZD0473 treatment in lung cancer: an overview of the clinical trial results.
|
|
Academic Article
|
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial.
|
|
Academic Article
|
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials.
|
|
Academic Article
|
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
|
|
Academic Article
|
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
|
|
Academic Article
|
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
|
|
Academic Article
|
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
|
|
Academic Article
|
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
|
|
Academic Article
|
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
|
|
Academic Article
|
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
|
|
Academic Article
|
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
|
|
Academic Article
|
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
|
|
Academic Article
|
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
|
|
Academic Article
|
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
|
|
Academic Article
|
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
|
|
Academic Article
|
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
|
|
Academic Article
|
Treatment of locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Locally advanced NSCLC: current state of the art, treatment and future directions.
|
|
Academic Article
|
Implications of key trials in advanced nonsmall cell lung cancer.
|
|
Academic Article
|
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
|
|
Academic Article
|
Lung cancer: new developments point the way to reduced mortality.
|
|
Academic Article
|
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
|
|
Academic Article
|
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
|
|
Academic Article
|
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
|
|
Academic Article
|
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
|
|
Academic Article
|
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
|
|
Academic Article
|
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.
|
|
Academic Article
|
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
|
|
Academic Article
|
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
|
|
Academic Article
|
Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer.
|
|
Academic Article
|
Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer.
|